MBRX icon

Moleculin Biotech
MBRX

Overview Fund Activity

26 hedge funds and large institutions have $3.16M invested in Moleculin Biotech in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.

Holders
26
Holders Change
–
Holders Change %
0%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Jane Street
1
Jane Street
New York
$21K
2
Citadel Advisors
2
Citadel Advisors
Florida
$14K
3
Envestnet Asset Management
3
Envestnet Asset Management
Illinois
$12K
4
UBS Group
4
UBS Group
Switzerland
$11K
5
TRCT
5
Tower Research Capital (TRC)
New York
$10K

Top Sellers

1
Charles Schwab
1
Charles Schwab
California
$0
2
Two Sigma Advisers
2
Two Sigma Advisers
New York
$0
3
Renaissance Technologies
3
Renaissance Technologies
New York
$90K
4
BlackRock
4
BlackRock
New York
$278K
5
CAPTRUST Financial Advisors
5
CAPTRUST Financial Advisors
North Carolina
$0
Name Market Value Shares Shares
Change 		Shares
Change %
NSIM
26
North Star Investment Management
Illinois
$0 17 – –
CFGS
27
Concourse Financial Group Securities
Alabama
– – – –
Wells Fargo
28
Wells Fargo
California
$0 13 – –
MPWT
29
MassMutual Private Wealth & Trust
Connecticut
$0 11 – –
GRP
30
Global Retirement Partners
California
$0 11 – –
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$0 17 +17 New
1
2